Technical Analysis for PHAS - PhaseBio Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 4.85 -1.82% -0.09
PHAS closed down 1.82 percent on Thursday, September 19, 2019, on 62 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical PHAS trend table...

Date Alert Name Type % Chg
Death Cross Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Wide Bands Range Expansion -1.82%
Oversold Stochastic Weakness -1.82%
Wide Bands Range Expansion 2.11%
Oversold Stochastic Weakness 2.11%

Older signals for PHAS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. It is also developing PB1046, a fusion protein currently in a Phase 2b clinical trial for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is based in Malvern, Pennsylvania.
Biopharmaceutical Surgery Chemical Compounds Organic Compounds Pulmonary Arterial Hypertension Pulmonary Hypertension Orphan Diseases
Is PHAS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 16.65
52 Week Low 2.55
Average Volume 144,819
200-Day Moving Average 7.795
50-Day Moving Average 7.7906
20-Day Moving Average 6.4915
10-Day Moving Average 5.099
Average True Range 0.6972
ADX 28.27
+DI 16.1342
-DI 31.136
Chandelier Exit (Long, 3 ATRs ) 7.733399999999999
Chandelier Exit (Short, 3 ATRs ) 6.6316
Upper Bollinger Band 9.5914
Lower Bollinger Band 3.3916
Percent B (%b) 0.24
BandWidth 95.506431
MACD Line -0.9485
MACD Signal Line -0.855
MACD Histogram -0.0935
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.26
Resistance 3 (R3) 5.28 5.18 5.19
Resistance 2 (R2) 5.18 5.07 5.16 5.16
Resistance 1 (R1) 5.01 5.01 4.96 4.99 5.14
Pivot Point 4.91 4.91 4.88 4.89 4.91
Support 1 (S1) 4.74 4.80 4.69 4.72 4.56
Support 2 (S2) 4.64 4.74 4.62 4.54
Support 3 (S3) 4.47 4.64 4.51
Support 4 (S4) 4.45